首页 > 市场调查报告书 > 医疗设备

体外诊断癌症液体活检

乳癌液态生物检体市场规模、份额和成长分析（按循环生物标记、应用和地区划分）—产业预测，2026-2033年

市场调查报告书

商品编码

1897987

乳癌液态生物检体市场规模、份额和成长分析（按循环生物标记、应用和地区划分）—产业预测，2026-2033年

Breast Cancer Liquid Biopsy Market Size, Share, and Growth Analysis, By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-Free Dna), By Application (Early Detection/Screening, Diagnosis), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，乳癌液态生物检体市场规模将达到 5.117 亿美元，到 2025 年将增长至 6.2785 亿美元，到 2033 年将增长至 32.2562 亿美元，在预测期（2026-2033 年）内复合增长率为 22.7%。

乳癌液态生物检体市场正经历显着成长，这主要得益于人们对非侵入性诊断解决方案的认知度和接受度不断提高。这项创新技术能够识别肿瘤特异性基因突变、循环性肿瘤细胞和游离DNA，为早期检测、个人化治疗策略和疗效监测提供关键资讯。持续的技术进步有望提高这些诊断测试的敏感度和特异性，从而进一步推动市场扩张。此外，生物技术公司与医疗机构的合作以及对个人化治疗日益增长的需求也推动了市场的发展。随着医学界越来越多地采用这种方法，乳癌液态生物检体行业有望迎来显着增长，并从根本上改变癌症的诊断和治疗方式。

乳癌液态生物检体市场驱动因素

液态生物检体技术的广泛应用正在推动乳癌液态生物检体市场的发展。与传统的组织切片检查相比，液态生物检体具有显着优势，它能够评估血液样本中的循环性肿瘤细胞（CTC）、游离DNA（cfDNA）以及各种生物标记。这种创新方法使医疗专业人员能够根据患者的个人需求制定更明智的治疗方案。此外，液态生物检体还可以检测抗药性突变和微量残存疾病，有助于制定个人化治疗策略，在改善患者预后的同时降低医疗成本。随着这些技术的日益普及，它们对患者照护的影响也日益显着。

乳癌液态生物检体市场的限制因素

乳癌液态生物检体市场面临诸多限制因素，主要原因在于这些先进诊断检测的高成本。液态生物检体技术的研究、开发和实施费用可能相当可观，从而加重患者的经济负担。对于经济资源有限或医疗资源匮乏的患者而言，这种情况尤其严峻，他们可能难以承担检测费用。此外，复杂的报销政策和监管要求也可能阻碍液态生物检体的广泛应用，并限制其在不同医疗机构的普及。因此，解决这些成本相关的障碍并优化报销机制对于提高乳癌患者普遍获得液态生物检体的机会至关重要。

乳癌液态生物检体市场趋势

乳癌液态生物检体市场呈现显着上升趋势，这主要得益于人们对能够早期发现和后续观察乳癌的非侵入性诊断技术的日益关注。鑑于液态生物检体具有许多优势，例如出结果更快、患者不适感更低以及能够捕捉肿瘤异质性，医疗服务提供者和患者正越来越多地寻求传统组织切片检查的替代方案。此外，检测技术的进步和人们对个人化医疗日益增长的兴趣也推动了市场成长。这一趋势反映了肿瘤学领域在癌症诊断和治疗方面转向以患者为中心、更个人化的转变。

F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories Inc.
Illumina Inc.
Guardant Health Inc.
QIAGEN
Biocept Inc.
Thermo Fisher Scientific
Adaptive Biotechnologies
Myriad Genetics
Fluxion Biosciences Inc.
Biodesix
Exosome Diagnostics Inc.
Epic Sciences
PapGene
Pathway Genomics（OME Care）
Agena Bioscience
MDxHealth
Janssen Diagnostics
Abbott

结论与建议

简介目录

Product Code: SQMIG35J2098

Breast Cancer Liquid Biopsy Market size was valued at USD 511.7 Million in 2024 and is poised to grow from USD 627.85 Million in 2025 to USD 3225.62 Million by 2033, growing at a CAGR of 22.7% during the forecast period (2026-2033).

The breast cancer liquid biopsy market is witnessing remarkable growth fueled by increased awareness and acceptance of non-invasive diagnostic solutions. This innovative technology's capacity to identify tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA offers vital insights for early detection, tailored treatment strategies, and monitoring responses to therapies. Ongoing advancements are set to enhance the sensitivity and specificity of these diagnostic tests, further propelling market expansion. Additionally, collaborations between biotech firms and healthcare providers, alongside a rising demand for personalized therapies, are contributing to the market's momentum. As the medical community increasingly adopts this approach, the breast cancer liquid biopsy industry is poised for substantial growth, fundamentally transforming cancer diagnostics and management practices.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Liquid Biopsy Market Segments Analysis

Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Liquid Biopsy Market

The growing utilization of liquid biopsy methods significantly propels the breast cancer liquid biopsy market. Liquid biopsies offer a distinct advantage over conventional tissue biopsies by facilitating the evaluation of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovative approach empowers healthcare professionals to make more informed treatment decisions tailored to individual patient needs. Moreover, liquid biopsies can detect resistance mutations and minimal residual disease, contributing to personalized treatment strategies that enhance patient outcomes while simultaneously lowering healthcare expenses. As these techniques gain traction, their impact on patient care remains increasingly notable.

Restraints in the Breast Cancer Liquid Biopsy Market

The breast cancer liquid biopsy market faces notable constraints, primarily due to the high costs associated with these advanced diagnostic tests. The expenses related to the research, development, and implementation of liquid biopsy technologies can be substantial, leading to increased financial burdens on patients. This situation is particularly challenging for individuals with limited financial means or those living in areas with insufficient healthcare funding, as the tests may become prohibitively expensive. Furthermore, complexities surrounding reimbursement policies and regulatory requirements can impede the broader adoption of liquid biopsy, restricting its availability in various healthcare environments. Addressing these cost-related barriers and optimizing reimbursement frameworks is crucial for improving accessibility to liquid biopsy for breast cancer patients universally.

Market Trends of the Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy market is experiencing a significant upward trend, driven by a rising emphasis on non-invasive diagnostic techniques that enable early detection and ongoing monitoring of breast cancer. Healthcare providers and patients are increasingly seeking alternatives to traditional tissue biopsies, given the advantages of liquid biopsies, which include faster results, reduced patient discomfort, and the ability to capture tumor heterogeneity. Additionally, advancements in detection technologies and a burgeoning focus on personalized medicine are propelling market growth. This trend reflects a broader shift in oncology towards more patient-centric and tailored approaches to cancer diagnosis and management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Case Study Analysis

Global Breast Cancer Liquid Biopsy Market Size by Circulating Biomarkers & CAGR (2026-2033)

Market Overview
Circulating Tumor Cells (CTCS)
Circulating Cell-Free DNA (CFDNA)
Extracellular Vesicles (EVS)
Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market Size by Application & CAGR (2026-2033)

Market Overview
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

Global Breast Cancer Liquid Biopsy Market Size by End Users & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Others

Global Breast Cancer Liquid Biopsy Market Size & CAGR (2026-2033)

North America (Circulating Biomarkers, Application, End Users)
- USA
- Canada
Europe (Circulating Biomarkers, Application, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Circulating Biomarkers, Application, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Circulating Biomarkers, Application, End Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Circulating Biomarkers, Application, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fluxion Biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biodesix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosome Diagnostics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PapGene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pathway Genomics (OME Care)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agena Bioscience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MDxHealth
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments